Author

Y. Haupt

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

S. Haupt· 2 shared A. Parker· 1 shared A. Swarbrick· 1 shared A. Yong· 1 shared B. Z. Zhang· 1 shared C. E. Caldon· 1 shared C. S. Cabalag· 1 shared D. S. Liu· 1 shared

Activity by Year

2020-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

S. Haupt

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

SLC7A11 is a superior determinant of APR-246 (Eprenetapopt) response than TP53 mutation status

K. M. Fujihara, M. Corrales-Benitez, C. S. Cabalag, B. Z. Zhang, H. S. Ko, D. S. Liu, K. J. Simpson, Y. Haupt, S. Haupt, W. A. Phillips, N. J. Clemons

This study identifies SLC7A11 expression as a better predictor of response to APR-246 than TP53 mutation status using cell line data and functional validation.

bioRxiv · Nov 29, 2020Cancer Biology

MDM2 Inhibition in Combination with Endocrine Therapy and CDK4/6 Inhibition for the Treatment of ER-Positive Breast Cancer.

N. Portman, H. H. Milioli, S. Alexandrou, R. Coulson, A. Yong, K. J. Fernandez, K. Chia, D. Segara, A. Parker, S. Haupt, Y. Haupt, W. D. Tilley, A. Swarbrick, C. E. Caldon, E. Lim

This study evaluates MDM2 inhibition combined with endocrine therapy and CDK4/6 inhibition in ER-positive breast cancer, showing synergistic anti-tumor effects in resistant models.

bioRxiv · Jun 9, 2020Cancer Biology